1103 related articles for article (PubMed ID: 27169802)
1. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease.
Brier MR; Gordon B; Friedrichsen K; McCarthy J; Stern A; Christensen J; Owen C; Aldea P; Su Y; Hassenstab J; Cairns NJ; Holtzman DM; Fagan AM; Morris JC; Benzinger TL; Ances BM
Sci Transl Med; 2016 May; 8(338):338ra66. PubMed ID: 27169802
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
3. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.
Chiaravalloti A; Barbagallo G; Ricci M; Martorana A; Ursini F; Sannino P; Karalis G; Schillaci O
Brain Res; 2018 Jan; 1678():116-122. PubMed ID: 29066367
[TBL] [Abstract][Full Text] [Related]
4. Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease.
Cohen AD; Landau SM; Snitz BE; Klunk WE; Blennow K; Zetterberg H
Mol Cell Neurosci; 2019 Jun; 97():3-17. PubMed ID: 30537535
[TBL] [Abstract][Full Text] [Related]
5. The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging.
Gordon BA; Friedrichsen K; Brier M; Blazey T; Su Y; Christensen J; Aldea P; McConathy J; Holtzman DM; Cairns NJ; Morris JC; Fagan AM; Ances BM; Benzinger TL
Brain; 2016 Aug; 139(Pt 8):2249-60. PubMed ID: 27286736
[TBL] [Abstract][Full Text] [Related]
6. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.
Petrie EC; Cross DJ; Galasko D; Schellenberg GD; Raskind MA; Peskind ER; Minoshima S
Arch Neurol; 2009 May; 66(5):632-7. PubMed ID: 19433663
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.
Wang L; Benzinger TL; Su Y; Christensen J; Friedrichsen K; Aldea P; McConathy J; Cairns NJ; Fagan AM; Morris JC; Ances BM
JAMA Neurol; 2016 Sep; 73(9):1070-7. PubMed ID: 27454922
[TBL] [Abstract][Full Text] [Related]
9. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
Watanabe H
Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
[TBL] [Abstract][Full Text] [Related]
10. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
Hake A; Trzepacz PT; Wang S; Yu P; Case M; Hochstetler H; Witte MM; Degenhardt EK; Dean RA;
Alzheimers Dement; 2015 Aug; 11(8):986-93. PubMed ID: 25916563
[TBL] [Abstract][Full Text] [Related]
11. PET Tau and Amyloid-β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers.
Koychev I; Gunn RN; Firouzian A; Lawson J; Zamboni G; Ridha B; Sahakian BJ; Rowe JB; Thomas A; Rochester L; Ffytche D; Howard R; Zetterberg H; MacKay C; Lovestone S;
J Alzheimers Dis; 2017; 60(1):283-293. PubMed ID: 28800330
[TBL] [Abstract][Full Text] [Related]
12. Dissociation of amyloid biomarkers in PET and CSF in Alzheimer's disease: a case report.
Schroeter ML; Tiepolt S; Marschhauser A; Thöne-Otto A; Hoffmann KT; Barthel H; Obrig H; Sabri O
BMC Neurol; 2015 Aug; 15():152. PubMed ID: 26303364
[TBL] [Abstract][Full Text] [Related]
13. Subthreshold Amyloid Predicts Tau Deposition in Aging.
Leal SL; Lockhart SN; Maass A; Bell RK; Jagust WJ
J Neurosci; 2018 May; 38(19):4482-4489. PubMed ID: 29686045
[TBL] [Abstract][Full Text] [Related]
14. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
[TBL] [Abstract][Full Text] [Related]
15. Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia.
Lowe VJ; Wiste HJ; Senjem ML; Weigand SD; Therneau TM; Boeve BF; Josephs KA; Fang P; Pandey MK; Murray ME; Kantarci K; Jones DT; Vemuri P; Graff-Radford J; Schwarz CG; Machulda MM; Mielke MM; Roberts RO; Knopman DS; Petersen RC; Jack CR
Brain; 2018 Jan; 141(1):271-287. PubMed ID: 29228201
[TBL] [Abstract][Full Text] [Related]
16. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
Weise D; Tiepolt S; Awissus C; Hoffmann KT; Lobsien D; Kaiser T; Barthel H; Sabri O; Gertz HJ
J Alzheimers Dis; 2015; 48(2):425-32. PubMed ID: 26402006
[TBL] [Abstract][Full Text] [Related]
17. Functional correlates of t-Tau, p-Tau and Aβ₁₋₄₂ amyloid cerebrospinal fluid levels in Alzheimer's disease: a ¹⁸F-FDG PET/CT study.
Chiaravalloti A; Martorana A; Koch G; Toniolo S; di Biagio D; di Pietro B; Schillaci O
Nucl Med Commun; 2015 May; 36(5):461-8. PubMed ID: 25646706
[TBL] [Abstract][Full Text] [Related]
18. Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease.
Wang L; Benzinger TL; Hassenstab J; Blazey T; Owen C; Liu J; Fagan AM; Morris JC; Ances BM
Neurology; 2015 Mar; 84(12):1254-60. PubMed ID: 25716355
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
20. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
Susanto TA; Pua EP; Zhou J;
J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
